MEHMET MUSTAFA ÖZASLAN, GÖKSEL TURHAL, MEHMET FATİH ÖĞÜT, HANDAN DUMAN ŞENOL, MERAL BARLIK, FEVZİYE ÇOKSÜER, GÖKÇEN KARTAL ÖZTÜRK, BAHAR GİRGİN DİNDAR, FİGEN GÜLEN, ESEN DEMİR
The Journal of Pediatric Research - 2025;12(2):75-82
Aim This study aimed to examine the effects of aminoglycoside (AG) antibiotics on hearing in children with cystic fibrosis (CF), to determine the risk factors for ototoxicity and the most appropriate audiological tests. Materials and Methods This was a retrospective observational study. Hearing tests of CF patients who were regularly followed up in our pediatric chest disease clinic and who had undergone hearing tests between January 2017 and December 2021 were evaluated. All patients underwent standard pure tone audiometry (PTA), extended high-frequency (EHF) PTA, and distortion product otoacoustic emission tests. RESULTS This study included 65 patients, aged 5-18 years, who were diagnosed with CF in two groups, one being a study group treated with AG (n=40) and the other being a control group not exposed to AG (n=25). Ototoxicity was determined in 30% of the patients treated with intravenous AG and in 4% of the control group. There was seen to be a high risk of ototoxicity in those patients who received ≥8 cycles of AG. The hearing thresholds at high frequencies, such as 16,000 hertz, were determined to be higher in the right and left ears of the AG treated group in comparison to the control group (p=0.025, p=0.001). Ototoxicity was determined in 2 more patients at high frequency which could not be determined in PTA. CONCLUSION Patients with CF for whom AG antibiotics are frequently used should be followed up at certain intervals with EHF PTA, which is more sensitive, even when there are no complaints.
